Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

luxeptinib (CG-806)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Aptose Biosci, CG Invites

Drug class:

BTK inhibitor, FLT3 inhibitor, Myeloid kinome inhibitor, Lymphoid kinome inhibitor

Related drugs:

‹

flonoltinib (0)

ibrutinib (186)

zanubrutinib (55)

acalabrutinib (41)

orelabrutinib (23)

pirtobrutinib (14)

abivertinib (1)

DTRMWXHS-12 (0)

tirabrutinib (0)

quizartinib (40)

ripretinib (11)

pexidartinib (6)

flonoltinib (0)

›

FLT3‐ITD	Acute Myelogenous Leukemia	FLT3‐ITD	Acute Myelogenous Leukemia	CG-806 Sensitive: C3 – Early Trials CG-806 Sensitive : C3	CG-806 Sensitive: C3 – Early Trials CG-806 Sensitive : C3
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	CG-806 Sensitive: C4 – Case Studies CG-806 Sensitive : C4	CG-806 Sensitive: C4 – Case Studies CG-806 Sensitive : C4
TNFSF13B negative	Non-Hodgkin’s Lymphoma	TNFSF13B negative	Non-Hodgkin’s Lymphoma	CG-806 Sensitive: D – Preclinical CG-806 Sensitive : D	CG-806 Sensitive: D – Preclinical CG-806 Sensitive : D
CD40L negative	Non-Hodgkin’s Lymphoma	CD40L negative	Non-Hodgkin’s Lymphoma	CG-806 Sensitive: D – Preclinical CG-806 Sensitive : D	CG-806 Sensitive: D – Preclinical CG-806 Sensitive : D
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	CG-806 Sensitive: D – Preclinical CG-806 Sensitive : D	CG-806 Sensitive: D – Preclinical CG-806 Sensitive : D
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	venetoclax + CG-806 Sensitive: D – Preclinical venetoclax + CG-806 Sensitive : D	venetoclax + CG-806 Sensitive: D – Preclinical venetoclax + CG-806 Sensitive : D